These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33024200)

  • 1. Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer.
    Le Goux C; Vacher S; Schnitzler A; Barry Delongchamps N; Zerbib M; Peyromaure M; Sibony M; Allory Y; Bieche I; Damotte D; Pignot G
    Sci Rep; 2020 Oct; 10(1):16641. PubMed ID: 33024200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
    Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
    Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
    Dueñas M; Martínez-Fernández M; García-Escudero R; Villacampa F; Marqués M; Saiz-Ladera C; Duarte J; Martínez V; Gómez MJ; Martín ML; Fernández M; Castellano D; Real FX; Rodriguez-Peralto JL; De La Rosa F; Paramio JM
    Mol Carcinog; 2015 Jul; 54(7):566-76. PubMed ID: 24347284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
    Kompier LC; Lurkin I; van der Aa MN; van Rhijn BW; van der Kwast TH; Zwarthoff EC
    PLoS One; 2010 Nov; 5(11):e13821. PubMed ID: 21072204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene mutation detection of urinary sediment cells for NMIBC early diagnose and prediction of NMIBC relapse after surgery.
    Zhu F; Zhang Y; Shi L; Wu CL; Chen SQ; Zheng H; Song DK
    Medicine (Baltimore); 2019 Aug; 98(32):e16451. PubMed ID: 31393349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
    Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
    Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer.
    Damrauer JS; Roell KR; Smith MA; Sun X; Kirk EL; Hoadley KA; Benefield HC; Iyer G; Solit DB; Milowsky MI; Kim WY; Nielsen ME; Wobker SE; Dalbagni G; Al-Ahmadie HA; Olshan AF; Bochner BH; Furberg H; Troester MA; Pietzak EJ
    Clin Cancer Res; 2021 Aug; 27(16):4599-4609. PubMed ID: 34117034
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Batista R; Lima L; Vinagre J; Pinto V; Lyra J; Máximo V; Santos L; Soares P
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.
    Fujita N; Hatakeyama S; Okita K; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2021 Mar; 39(3):191.e9-191.e16. PubMed ID: 32713622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Molecular Signature Determines the Prognostic and Therapeutic Subtype of Non-Muscle-Invasive Bladder Cancer Responsive to Intravesical Bacillus Calmette-Guérin Therapy.
    Kim SK; Park SH; Kim YU; Byun YJ; Piao XM; Jeong P; Kim K; Lee HY; Seo SP; Kang HW; Kim WT; Kim YJ; Lee SC; Moon SK; Choi YH; Kim WJ; Kim SY; Yun SJ
    Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33535616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
    Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
    Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer.
    Avgeris M; Tsilimantou A; Levis PK; Rampias T; Papadimitriou MA; Panoutsopoulou K; Stravodimos K; Scorilas A
    Carcinogenesis; 2019 Aug; 40(8):965-974. PubMed ID: 30815670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
    Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
    Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.
    van Kessel KEM; van der Keur KA; Dyrskjøt L; Algaba F; Welvaart NYC; Beukers W; Segersten U; Keck B; Maurer T; Simic T; Horstmann M; Grimm MO; Hermann GG; Mogensen K; Hartmann A; Harving N; Petersen AC; Jensen JB; Junker K; Boormans JL; Real FX; Malats N; Malmström PU; Ørntoft TF; Zwarthoff EC
    Clin Cancer Res; 2018 Apr; 24(7):1586-1593. PubMed ID: 29367430
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer.
    Abdelrahman AE; Rashed HE; Elkady E; Elsebai EA; El-Azony A; Matar I
    Ann Diagn Pathol; 2019 Apr; 39():42-52. PubMed ID: 30684846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic diversity of urinary bladder cancer and the risk of recurrence based on mutation analysis.
    Traczyk-Borszynska M; Borkowska E; Jablonowski Z; Jedrzejczyk A; Pietrusinski M; Kaluzewski B; Sosnowski M; Borowiec M
    Neoplasma; 2016; 63(6):952-960. PubMed ID: 27596295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.